Ke Zhu

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Ke Zhu is a seasoned corporate transactional lawyer who specializes in Hong Kong IPOs, large-scale cross-border mergers and acquisitions, and private equity investments. He has represented a number of PRC and international companies in connection with Hong Kong public offerings and cross-border mergers and acquisitions.

Ke is well versed in highly complex and critical corporate transactions and works tenaciously to achieve successful results on behalf of his clients. He is responsive, highly skilled, and dedicated to the sustainability and success of his clients.

VIEW MORE

Languages

  • Mandarin Chinese

Admissions

Bar Admission

  • New York
  • Hong Kong

Education

  • Columbia University, LL.M.
  • University of Oxford Faculty of Law, LL.M.
  • Huazhong University Science & Technology, LL.B.

Professional Activities

Member

  • American Bar Association
  • Hong Kong Law Society

IPO Transactions

  • Represented Viva Biotech in its HK$1,521.5 million (approximately US$194 million) initial public offering on the Main Board of the Hong Kong Stock Exchange
  • Represented Holly Futures Co., Ltd., a leading China-based futures company, in its US$63 million initial public offering of H-shares on the Main Board of the Hong Kong Stock Exchange
  • Represented UBS as sole global coordinators, bookrunner, lead manager and sponsor in the US$106 million initial public offering of China Huirong Financial Holdings Ltd. on the Main Board of the Hong Kong Stock Exchange
  • Represented Morgan Stanley and CCBI as joint sponsors and joint global coordinators in the US$250 million initial public offering of Harmonicare Medical Holdings Limited on the Main Board of the Hong Kong Stock Exchange
  • Represented Chanjet Information Technology Company Limited in the US$116 million initial public offering of its H-shares on the Main Board of the Hong Kong Stock Exchange. This was the first spin-off listing of an A-share listed company on the Hong Kong Stock Exchange
  • Represented China Vanke Co., Ltd. in the conversion of US$2.1 billion B-shares into H-shares and the listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction
  • Represented Guosen Securities (HK) Capital Company Limited as sole sponsor in the conversion of Livzon Pharmaceutical Group Inc.'s US$548 million B-shares into H-shares and listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction
  • Represented China International Marine Containers (Group) Co., Ltd. in the conversion of US$1.8 billion B-shares into H-shares and listing of the H-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction. This was the first B-to-H listing on the Hong Kong Stock Exchange
  • Represented CITIC Securities, UBS, and Bank of America Merrill Lynch as joint global coordinators and other underwriters in the US$319 million initial public offering of the H-shares of Huadian Fuxin Energy Corporation on the Main Board of the Hong Kong Stock Exchange
  • Represented Haitong Securities Co. Ltd. in the US$1.68 billion initial public offering of its H-shares on the Main Board of the Hong Kong Stock Exchange
  • Represented Morgan Stanley, Citigroup, and Credit Suisse as joint global coordinators and other syndicate of banks in the US$12 billion global offering and dual listing of Glencore International in both London and Hong Kong
  • Represented CICC and Morgan Stanley as joint sponsors in the listing of Guangzhou Auto by way of introduction through privatization of a HK-listed auto company on the Main Board of the Hong Kong Stock Exchange
  • Represented Microport Scientific Corporation in its US$200 million initial public offering on the Main Board of the Hong Kong Stock Exchange 

Mergers and Acquisitions

  • Represented Nat-Ace Pharmaceutical in its US$35 million acquisition of approximately 52.79% equity interest in the HK-listed Perception Digital Holdings Limited from its then controlling shareholders by way of an unconditional, mandatory cash offer to acquire all the issued shares and cancel all outstanding options
  • Represented Geely Automobile in its acquisition of Volvo Group from Ford Group at US$1.8 billion
  • Represented Newbridge Capital in its sale of approximately 16.67% equity interest in Shenzhen Development Bank to Ping An Insurance at US$1.68 billion
  • Represented China International Marine Containers (CIMC), in connection with its wholly owned subsidiary CIMC Hong Kong, in its sale of 70% equity interest in CIMC-TianDa to Pteris Global Limited (Pteris). As consideration, Pteris would issue US$75 million new shares to CIMC Hong Kong for its reverse takeover and become a subsidiary of CIMC. This transaction was deemed a new listing of Pteris on the Singapore Exchange
  • Represented Tenwow International in its pre-IPO investments in several rounds of bidding and accepting offers from various pre-IPO investors immediately before its US$203 million initial public offering on the Main Board of the Hong Kong Stock Exchange